Scinai Immunotherapeutics Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $16.6M
- Price
- $3.22
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.52%
- Volume
- 428.4K
About
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Quick stats
Shares outstanding5.2M
Computed float5.2M
Float / shares100.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001611747
Websitehttps://www.scinai.com
AI Summary
AI-generated1/5
minorbullishexecutive change
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Scinai Immunotherapeutics appointed Eran Kuratz as Head of Supply Chain and Business Process Administration for its CDMO subsidiary, Scinai Biopharma Services.
Kuratz, who reports to CEO Amir Reichman, brings over 30 years of experience and will oversee procurement, logistics, IT, and quality management systems.
The hire supports the integration of Scinai's expanded CDMO platform following the Q1 2026 acquisition of Recipharm Israel.